Bristol-Myers Squibb (BMY) announced Monday morning that its Phase 3 study, of Opdivo 3 mg/kg plus low-dose Yervoy in first-line advanced non-small cell lung cancer patients reduced the risk of death by 42% versus chemotherapy alone.
from RTT - Before the Bell https://ift.tt/2J5mdHJ
via IFTTT
No comments:
Post a Comment